-
Merck & Cie et al v. Lupin Ltd. et al DC
- 1:15-cv-00407
- D. Del.
- Filed: 05/20/2015
- Closed: 11/10/2016
- Latest Docket Entry: 11/21/2016
- Judge: Richard G. Andrews
- PACER
3
Plaintiffs
2
Defendants
1
Accused
Product
1
Patent-in-Suit
541
Days in
Litigation
-
Merck & Cie et al v. Lupin Ltd. et al DC
- 1:15-cv-00407
- D. Del.
- Filed: 05/20/2015
- Closed: 11/10/2016
- Latest Docket Entry: 11/21/2016
- Judge: Richard G. Andrews
- PACER
Cause of Action
Infringement
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 4 |
A crystalline calcium salt of 5-methyl-(6S)-tetrahydrofolic acid with 2 theta values of 6.5, 13.3, 16.8 and 20.1 (Type I) said crystalline salt having a water of crystallization of at least one equivalent per equivalent of 5-methyltetrahydrofolic
view more
|
Invalid (102)
Entry 35 |
-
Infringement
Lupin Limited
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 24 tablets comprising Generic 3 mg of micronized drospirenone, 0.02 mg of micronized 17α-ethinylestradiol, 0.451 mg levomefolate calcium plus 4 tablets comprising 0.451 mg levomefolate calcium | US 6,441,168 B1 |
4
|
No infringement
Entry 35
|
Lupin Pharmaceuticals Incorporated
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 24 tablets comprising Generic 3 mg of micronized drospirenone, 0.02 mg of micronized 17α-ethinylestradiol, 0.451 mg levomefolate calcium plus 4 tablets comprising 0.451 mg levomefolate calcium | US 6,441,168 B1 |
4
|
No infringement
Entry 35
|